Skip to main content

Mapping Cancer Response using Organoids and Mass cytometry

Project description

Cancer patient organoids to guide treatment

Tumours are characterised by great heterogeneity which often impedes drug effectiveness. Therefore, cancer models used in drug development must reflect disease properties in order to recapitulate their drug response. The EU-funded MaCaROM project proposes to use organoids derived from breast cancer patient samples to meet this challenge. Using mass cytometry, scientists will evaluate response of heterogeneous cancer models to different FDA-approved drugs at the single-cell level. Results will provide important information on drug sensitivity and resistance, supporting treatment decisions for improved clinical outcome and increased patient survival.


Net EU contribution
€ 191 149,44
Ramistrasse 71
8006 Zurich

See on map

Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Higher or Secondary Education Establishments
Other funding
€ 191 149,44